Abstract
Purpose
Naringenin has shown paradoxical results to modulate the function of multidrug resistance-associated proteins (MRPs). The aim of this study is to interpret whether naringenin can reverse intrinsic and/or acquired resistance of cancer cells to chemotherapeutic agents.
Methods
The effects of naringenin on the uptake, retention and cytotoxicity of doxorubicin were investigated in A549, MCF-7, HepG2 and MCF-7/DOX cells. Cellular efflux pathways modulated by naringenin were assessed with their specific substrates and inhibitors. The improved antitumor activity of doxorubicin in combination with naringenin was also investigated in vivo.
Results
The IC50 values of doxorubicin in combination with naringenin in A549 and MCF-7 cells were approximately 2-fold lower than that of doxorubicin alone. The increased sensitivity to doxorubicin by naringenin in HepG2 and MCF-7/DOX cells was not observed. Naringenin increased the cellular doxorubicin accumulation through inhibiting doxorubicin efflux in the cells expressing MRPs but not P-gp. In contrast to doxorubicin alone, doxorubicin in combination with naringenin enhanced antitumor activity in vivo with low systemic toxicity.
Conclusion
Naringenin enhances antitumor effect of doxorubicin by selective modulating drug efflux pathways. Naringenin will be a useful adjunct to improve the effectiveness of chemotherapeutic agents in treatment of human cancers.
Similar content being viewed by others
Abbreviations
- DMSO:
-
Dimethyl sulfoxide
- DOX:
-
Doxorubicin
- FITC:
-
Fluorescein isothiocyanate
- MRPs:
-
Multidrug resistance-associated proteins
- MTT:
-
Methylthiazoletetrazolium
- Nar:
-
Naringenin
- PBS:
-
Phosphate-buffered saline
- P-gp:
-
P-glycoprotein
- PI:
-
Propidium iodide
- Rho123:
-
Rhodamine 123
- Vrp:
-
Verapamil
- 5-CFDA:
-
5-Carboxyfluresceindiacetate
References
M. M. Gottesman, T. Fojo, and S. E. Bates. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2:48–58 (2002). doi:10.1038/nrc706.
M. Bredel. Anticancer drug resistance in primary human brain tumors. Brain Res. Brain Res. Rev. 35:161–204 (2001). doi:10.1016/S0165-0173(01)00045-5.
M. M. Gottesman, and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385–427 (1993). doi:10.1146/annurev.bi.62.070193.002125.
P. Borst, R. Evers, M. Kool, and J. Wijnholds. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295–1302 (2000). doi:10.1093/jnci/92.16.1295.
S. P. Cole, G. Bhardwaj, J. H. Gerlach, J. E. Mackie, C. E. Grant, K. C. Almquist, A. J. Stewart, E. U. Kurz, A. M. V. Duncan, and R. G. Deeley. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1650–1654 (1992). doi:10.1126/science.1360704.
L. A. Doyle, W. Yang, L. V. Abruzzo, T. Krogmann, Y. Gao, A. K. Rishi, and D. D. Ross. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA. 95:15665–15670 (1998). doi:10.1073/pnas.95.26.15665.
E. K. Rowinsky, L. Smith, Y. M. Wang, P. Chaturvedi, M. Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, L. Hammond, M. Kraynak, R. Drengler, J. Stephenson Jr., M. W. Harding, and D. D. Von Hoff. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 16:2964–2976 (1998).
R. A. Peck, J. Hewett, M. W. Harding, Y. M. Wang, P. R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins, and M. J. Hawkins. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J. Clin. Oncol. 19:3130–3141 (2001).
R. V. Kondratov, P. G. Komarov, Y. Becker, A. Ewenson, and A. V. Gudkov. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. USA. 98:14078–14083 (2001). doi:10.1073/pnas.241314798.
H. Minderman, K. L. O’Loughlin, L. Pendyala, and M. R. Baer. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 10:1826–1834 (2004). doi:10.1158/1078-0432.CCR-0914-3.
L. C. Young, B. G. Campling, S. P. Cole, R. G. Deeley, and J. H. Gerlach. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 7:1798–1804 (2001).
T. Abe, S. Hasegawa, K. Taniguchi, A. Yokomizo, T. Kuwano, M. Ono, T. Mori, S. Hori, K. Kohno, and M. Kuwano. Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and adriamycin in human glioma cells. Int. J. Cancer. 58:860–864 (1994). doi:10.1002/ijc.2910580619.
C. Calatozzolo, M. Gelati, E. Ciusani, F. L. Sciacca, B. Pollo, L. Cajola, C. Marras, A. Silvani, L. Vitellaro-Zuccarello, D. Croci, A. Boiardi, and A. Salmaggi. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J. Neurooncol. 74:113–121 (2005). doi:10.1007/s11060-004-6152-7.
A. T. Nies, J. König, M. Pfannschmidt, E. Klar, W. J. Hofmann, and D. Keppler. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer. 94:492–499 (2001). doi:10.1002/ijc.1498.
E. H. Rubin, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, Y. Lin, R. Musanti, S. L. Grospe, S. L. Smith, D. L. Toppmeyer, J. Much, M. Kane, A. Chaudhary, C. Jordan, M. Burgess, and C. A. Slapak. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin. Cancer Res. 8:3710–3717 (2002).
L. Gandhi, M. W. Harding, M. Neubauer, C. J. Langer, M. Moore, H. J. Ross, B. E. Johnson, and T. J. Lynch. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 109:924–932 (2007). doi:10.1002/cncr.22492.
S. Zhang, and M. E. Morris. Effects of the flavonoids biochanin A, morin, phloretin and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304:1258–1267 (2003). doi:10.1124/jpet.102.044412.
M. Hadjeri, M. Barbier, X. Ronot, A. M. Mariotte, A. Boumendjel, and J. Boutonnat. Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues. J. Med. Chem. 46:2125–2131 (2003). doi:10.1021/jm021099i.
S. Zhang, X. Yang, and M. E. Morris. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21:1263–1273 (2004). doi:10.1023/B:PHAM.0000033015.84146.4c.
J. J. van Zanden, H. M. Wortelboer, S. Bijlsma, A. Punt, M. Usta, P. J. Bladeren, I. M. Rietjens, and N. H. Cnubben. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 69:699–708 (2005). doi:10.1016/j.bcp.2004.11.002.
C. Zanini, G. Giribaldi, G. Mandili, F. Carta, N. Crescenzio, B. Bisaro, A. Doria, L. Foglia, L. C. di Montezemolo, F. Timeus, and F. Turrini. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing’s sarcoma cell lines. J. Neurochem. 103:1344–1354 (2007). doi:10.1111/j.1471-4159.2007.04835.x.
A. Bast, H. Kaiserová, G. J. den Hartog, G. R. Haenen, and W. J. van der Vijgh. Protectors against doxorubicin-induced cardiotoxicity: flavonoids. Cell Biol. Toxicol. 23:39–47 (2007). doi:10.1007/s10565-006-0139-4.
H. Kaiserová, T. Simůnek, W. J. van der Vijgh, A. Bast, and E. Kvasnicková. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochim. Biophys. Acta. 1772:1065–1074 (2007).
S. Zhang, X. Yang, and M. E. Morris. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65:1208–1216 (2004). doi:10.1124/mol.65.5.1208.
S. Kitagawa. Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol. Pharm. Bull. 29:1–6 (2006). doi:10.1248/bpb.29.1.
T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55–63 (1983). doi:10.1016/0022-1759(83)90303-4.
Y. Li, and F. H. Sarkar. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 8:2369–2377 (2002).
V. Jekerle, W. Klinkhammer, D. A. Scollard, K. Breitbach, R. M. Reilly, M. Piquette-Miller, and M. Wiese. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int. J. Cancer. 119:414–422 (2006). doi:10.1002/ijc.21827.
C. Kimchi-Sarfaty, J. M. Oh, I. W. Kim, Z. E. Sauna, A. M. Calcagno, S. V. Ambudkar, and M. M. Gottesman. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 315:525–528 (2007). doi:10.1126/science.1135308.
C. L. Hammond, R. Marchan, S. M. Krance, and N. Ballatori. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J. Biol. Chem. 282:14337–14347 (2007). doi:10.1074/jbc.M611019200.
V. Stierlé, A. Laigle, and B. Jollès. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs. Biochem. Pharmacol. 70:1424–1430 (2005).
M. Biscardi, E. Teodori, R. Caporale, R. Budriesi, F. Balestri, B. Scappini, S. Gavazzi, and A. Grossi. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity. Leuk. Res. 30:1–9 (2006).
E. Teodori, S. Dei, A. Garnier-Suillerot, F. Gualtieri, D. Manetti, C. Martelli, M. N. Romanelli, S. Scapecchi, P. Sudwan, and M. Salerno. Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. J. Med. Chem. 48:7426–7436 (2005). doi:10.1021/jm050542x.
P. Mitra, C. A. Oskeritzian, S. G. Payne, M. A. Beaven, S. Milstien, and S. Spiegel. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc. Natl. Acad. Sci. USA. 103:16394–16399 (2006). doi:10.1073/pnas.0603734103.
S. Kitagawa, T. Nabekura, T. Takahashi, Y. Nakamura, H. Sakamoto, H. Tano, M. Hirai, and G. Tsukahara. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol. Pharm. Bull. 28:2274–2278 (2005). doi:10.1248/bpb.28.2274.
G. A. Thomas, M. A. Barrand, S. Stewart, P. H. Rabbitts, E. D. Williams, and P. R. Twentyman. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur. J. Cancer. 30:1705–1709 (1994). doi:10.1016/0959-8049(94)00290-L.
C. M. Laurençot, G. L. Scheffer, R. J. Scheper, and R. H. Shoemaker. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer. 72:1021–1026 (1997). doi:10.1002/(SICI)1097-0215(19970917)72:6<1021::AID-IJC17>3.0.CO;2-7.
L. Beketic-Oreskovic, G. E. Durán, G. Chen, C. Dumontet, and B. I. Sikic. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J. Natl. Cancer Inst. 87:1593–1602 (1995). doi:10.1093/jnci/87.21.1593.
X. F. Hu, A. Slater, P. Kantharidis, D. Rischin, S. Juneja, R. Rossi, G. Lee, J. D. Parkin, and J. R. Zalcberg. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood. 93:4086–4095 (1999).
F. Zhang, G. Du, and W. Liang. Naringenin exerts its anti-tumor effect via antiangiogenesis. 8th world congress for microcirculation. Milwaukee, Wisconsin, USA, 2007, pp. 159–163.
F. Tosetti, N. Ferrari, S. De Flora, and A. Albini. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16:2–14 (2002). doi:10.1096/fj.01-0300rev.
H. M. Arafa, M. F. Abd-Ellah, and H. F. Hafez. Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats. J. Egypt Natl. Canc. Inst. 17:291–300 (2005).
Acknowledgments
This work was supported by grants from the State Key Development Plan Project (2006CB705706 and 2007CB935801), National Natural Science Foundation of China (90606019, 90713024) and the Chinese Academy of Sciences (KSCX2-YW-R-21 and KJCX2-YW-M02).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, F.Y., Du, G.J., Zhang, L. et al. Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein. Pharm Res 26, 914–925 (2009). https://doi.org/10.1007/s11095-008-9793-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9793-y